| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Metastatic cancer may emerge more than 10 years after complete remission in human breast cancers. It is considered that these very late relapses are caused by the latent tumor cells that remain dormant in the organs of metastases. In this research, we revealed that the cancer cells in the patient-derived xenografts of human breast cancers are mostly in a G0 phase; the presence of primary cilia is not associated with the cell-cycle arrest; and the downregulation of the chemokine receptor CXCR4 is associated with the cell-cycle arrest. Furthermore, we identified the microRNAs that are preferentially expressed in the cancer cells in the patient-derived xenografts of human breast cancers and revealed a part of the genes and signaling pathways regulated by these microRNAs.
|
